Prof. Šárka Pospíšilová, Ph.D.

Publications that are part of the Web of Science database, possibly also other publications chosen by authors.

2020

• Mancikova, V; Peschelova, H; Kozlova, V; Ledererova, A; Ladungova, A; Verner, J; Loja, T; Folber, F; Mayer, J; Pospisilova, S; Smida, M, 2020: Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia. JOURNAL FOR IMMUNOTHERAPY OF CANCER 8(1), doi: 10.1136/jitc-2019-000471
• Laidou, S; Alanis-Lobato, G; Pribyl, J; Rasko, T; Tichy, B; Mikulasek, K; Tsagiopoulou, M; Oppelt, J; Kastrinaki, G; Lefaki, M; Singh, M; Zink, A; Chondrogianni, N; Psomopoulos, F; Prigione, A; Ivics, Z; Pospisilova, S; Skladal, P; Izsvak, Z; Andrade-Navarro, MA; Petrakis, S, 2020: Nuclear inclusions of pathogenic ataxin-1 induce oxidative stress and perturb the protein synthesis machinery. REDOX BIOLOGY 32, doi: 10.1016/j.redox.2020.101458
• Malcikova, J; Pavlova, S; Vonkova, B; Kotaskova, J; Radova, L; Plevova, K; Zenatova, M; Hynst, J; Dvorackova, B; Panovska, A; Brychtova, Y; Tichy, B; Navrkalova, V; Pal, K; Mayer, J; Doubek, M; Pospisilova, S, 2020: Minor-clone TP53 mutations in CLL patients entering first-line treatment: clonal evolution and clinical impact. LEUKEMIA & LYMPHOMA 61, p. 222 - 224
• Komkov, A; Miroshnichenkova, A; Nugmanov, G; Popov, A; Pogorelyy, M; Zapletalova, E; Jelinkova, H; Pospisilova, S; Lebedev, Y; Chudakov, D; Olshanskaya, Y; Plevova, K; Maschan, M; Mamedov, I, 2020: High-throughput sequencing of T-cell receptor alpha chain clonal rearrangements at the DNA level in lymphoid malignancies. BRITISH JOURNAL OF HAEMATOLOGY 188(5), p. 723 - 731, doi: 10.1111/bjh.16230
• Kozlova, V; Ledererova, A; Mancikova, V; Mayer, J; Pospisilova, S; Doubek, M; Smida, M, 2020: Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells. LEUKEMIA & LYMPHOMA 61, p. 256 - 257
• Mancikova, V; Peschelova, H; Kozlova, V; Ledererova, A; Ladungova, A; Verner, J; Loja, T; Folber, F; Mayer, J; Pospisilova, S; Smida, M, 2020: Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia. JOURNAL FOR IMMUNOTHERAPY OF CANCER 8(1), doi: 10.1136/jitc-2019-000471
• Maurer, B; Nivarthi, H; Wingelhofer, B; Pham, HTT; Schlederer, M; Suske, T; Grausenburger, R; Schiefer, AI; Prchal-Murphy, M; Chen, D; Winkler, S; Merkel, O; Kornauth, C; Hofbauer, M; Hochgatterer, B; Hoermann, G; Hoelbl-Kovacic, A; Prochazkova, J; Lobello, C; Cumaraswamy, AA; Latzka, J; Kitzwogerer, M; Chott, A; Janikova, A; Pospisilova, S; Loizou, JI; Kubicek, S; Valent, P; Kolbe, T; Grebien, F; Kenner, L; Gunning, PT; Kralovics, R; Herling, M; Muller, M; Rulicke, T; Sexl, V; Moriggl, R, 2020: High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. HAEMATOLOGICA 105(2), p. 435 - 447, doi: 10.3324/haematol.2019.216986
• Nemcova, L; Nekvindova, L; Spacek, M; Simkovic, M; Papajik, T; Brejcha, M; Lysak, D; Zuchnicka, J; Novak, J; Starostka, D; Poul, H; Vrbacky, F; Urbanova, R; Panovska, A; Plevova, K; Pospisilova, S; Hrobkova, S; Koritakova, E; Smolej, L; Doubek, M, 2020: Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus bendamustine, and rituximab plus chlorambucil in front-line CLL therapy: The GO-CLLEAR Study by Czech CLL Study Group. LEUKEMIA & LYMPHOMA 61, p. 57 - 59

2019

• Taus, P; Plevova, K; Darzentas, N; Pal, K; Pospisilova, S, 2019: Identification of novel chronic lymphocytic leukemia subtypes using pathway mutation scores and consensus clustering. EUROPEAN JOURNAL OF HUMAN GENETICS 27, p. 1553 - 1554
• Bereshchenko, O; Lo Re, O; Nikulenkov, F; Flamini, S; Kotaskova, J; Mazza, T; Le Pannerer, MM; Buschbeck, M; Giallongo, C; Palumbo, G; Li Volti, G; Pazienza, V; Cervinek, L; Riccardi, C; Krejci, L; Pospisilova, S; Stewart, AF; Vinciguerra, M, 2019: Deficiency and haploinsufficiency of histone macroH2A1.1 in mice recapitulate hematopoietic defects of human myelodysplastic syndrome. CLINICAL EPIGENETICS 11(1), doi: 10.1186/s13148-019-0724-z
• Trizuljak, J; Doubkova, M; Hrazdirova, A; Vrzalova, Z; Blahakova, I; Radova, L; Pospisilova, S; Doubek, M, 2019: A rare diagnosis: Hermansky-Pudlak syndrome in a patient with pulmonary fibrosis, oculocutaneous albinism and thrombocytopathy. EUROPEAN JOURNAL OF HUMAN GENETICS 27, p. 1252 - 1252
• Spunarova, M; Tom, N; Pavlova, S; Mraz, M; Brychtova, Y; Doubek, M; Panovska, A; Francova, HS; Brzobohata, A; Pospisilova, S; Mayer, J; Trbusek, M, 2019: Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience. LEUKEMIA RESEARCH 81, p. 75 - 81, doi: 10.1016/j.leukres.2019.04.015
• Moysiadis, T; Baliakas, P; Rossi, D; Catherwood, M; Strefford, JC; Delgado, J; Anagnostopoulos, A; Belessi, C; Stavroyianni, N; Pospisilova, S; Oscier, D; Gaidano, G; Campo, E; Rosenquist, R; Ghia, P; Stamatopoulos, K, 2019: Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors. LEUKEMIA 33(7), p. 1801 - 1805, doi: 10.1038/s41375-018-0322-7
• Baliakas, P; Jeromin, S; Iskas, M; Puiggros, A; Plevova, K; Nguyen-Khac, F; Davis, Z; Rigolin, GM; Visentin, A; Xochelli, A; Delgado, J; Baran-Marszak, F; Stalika, E; Abrisqueta, P; Durechova, K; Papaioannou, G; Eclache, V; Dimou, M; Iliakis, T; Collado, R; Doubek, M; Calasanz, MJ; Ruiz-Xiville, N; Moreno, C; Jarosova, M; Leeksma, AC; Panayiotidis, P; Podgornik, H; Cymbalista, F; Anagnostopoulos, A; Trentin, L; Stavroyianni, N; Davi, F; Ghia, P; Kater, AP; Cuneo, A; Pospisilova, S; Espinet, B; Athanasiadou, A; Oscier, D; Haferlach, C; Stamatopoulos, K, 2019: Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. BLOOD 133(11), p. 1205 - 1216, doi: 10.1182/blood-2018-09-873083
• Hynst, J; Plevova, K; Radova, L; Bystry, V; Pali, K; Pospisilova, S, 2019: Bioinformatic pipelines for whole transcriptome sequencing data exploitation in leukemia patients with complex structural variants. PEERJ 7, doi: 10.7717/peerj.7071
• Doubkova, M; Kozubik, KS; Radova, L; Pesova, M; Trizuljak, J; Pal, K; Svobodova, K; Reblova, K; Svozilova, H; Vrzalova, Z; Pospisilova, S; Doubek, M, 2019: A novel germline mutation of the SFTPA1 gene in familial interstitial pneumonia. HUMAN GENOME VARIATION 6, doi: 10.1038/s41439-019-0044-z
• Condoluci, A; di Bergamo, LT; Langerbeins, P; Hoechstetter, M; Herling, C; De Paoli, L; Delgado, J; Rabe, KG; Gentile, M; Doubek, M; Mauro, FR; Chiodin, G; Mattsson, M; Bahlo, J; Cutrona, G; Kotaskova, J; Deambrogi, C; Spina, V; Bruscaggin, A; Moia, R; Bianchi, E; Gerber, B; Zucca, E; Ghielmini, M; Cavalli, F; Stussi, G; Neri, A; Ferrarini, M; Rosenquist, R; Forconi, F; Foa, R; Pospisilova, S; Morabito, F; Parikh, SA; Wierda, WG; Montserrat, E; Gaidano, G; Hallek, M; Rossi, D, 2019: International Prognostic Score (IPS-A) for Patients with Early Stage Chronic Lymphocytic Leukemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 19, p. S278 - S278, doi: 10.1016/j.clml.2019.07.212
• Vonkova, B; Blabakova, I; Hruban, L; Janku, P; Pospisilova, S, 2019: MicroRNA-210 expression during childbirth and postpartum as a potential biomarker of acute fetal hypoxia. BIOMEDICAL PAPERS-OLOMOUC 163(3), p. 259 - 264, doi: 10.5507/bp.2018.075
• Doubkova, M; Trizuljak, J; Vrzalova, Z; Hrazdirova, A; Blahakova, I; Radova, L; Pospisilova, S; Doubek, M, 2019: Novel genetic variant of HPS1 gene in Hermansky-Pudlak syndrome with fulminant progression of pulmonary fibrosis: a case report. BMC PULMONARY MEDICINE 19(1), doi: 10.1186/s12890-019-0941-4

2018

• Brazdilova, K; Plevova, K; Francova, HS; Kockova, H; Borsky, M; Bikos, V; Malcikova, J; Oltova, A; Kotaskova, J; Tichy, B; Brychtova, Y; Mayer, J; Doubek, M; Pospisilova, S, 2018: Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL. LEUKEMIA 32(1), p. 234 - 236, doi: 10.1038/leu.2017.274
• Trizuljak, J; Kozubik, KS; Radova, L; Pesova, M; Pal, K; Reblova, K; Stehlikova, O; Smejkal, P; Zavrelova, J; Pacejka, M; Mayer, J; Pospisilova, S; Doubek, M, 2018: A novel germline mutation in GP1BA gene N-terminal domain in monoallelic Bernard-Soulier syndrome. PLATELETS 29(8), p. 827 - 833, doi: 10.1080/09537104.2018.1529300
• Campo, E; Cymbalista, F; Ghia, P; Jager, U; Pospisilova, S; Rosenquist, R; Schuh, A; Stilgenbauer, S, 2018: TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. HAEMATOLOGICA 103(12), p. 1956 - 1968, doi: 10.3324/haematol.2018.187583
• Rawstron, AC; Kreuzer, KA; Soosapilla, A; Spacek, M; Stehlikova, O; Gambell, P; McIver-Brown, N; Villamor, N; Psarra, K; Arroz, M; Milani, R; de la Serna, J; Cedena, MT; Jaksic, O; Nomdedeu, J; Moreno, C; Rigolin, GM; Cuneo, A; Johansen, P; Johnsen, HE; Rosenquist, R; Niemann, CU; Kern, W; Westerman, D; Trneny, M; Mulligan, S; Doubek, M; Pospisilova, S; Hillmen, P; Oscier, D; Hallek, M; Ghia, P; Montserrat, E, 2018: Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. CYTOMETRY PART B-CLINICAL CYTOMETRY 94(1900-01-01T00:00:00.000), p. 121 - 128, doi: 10.1002/cyto.b.21595
• Kubesova, B; Pavlova, S; Malcikova, J; Kabathova, J; Radova, L; Tom, N; Tichy, B; Plevova, K; Kantorova, B; Fiedorova, K; Slavikova, M; Bystry, V; Kissova, J; Gisslinger, B; Gisslinger, H; Penka, M; Mayer, J; Kralovics, R; Pospisilova, S; Doubek, M, 2018: Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. LEUKEMIA 32(2), p. 450 - 461, doi: 10.1038/leu.2017.230
• Plesingerova, H; Janovska, P; Mishra, A; Smyckova, L; Poppova, L; Libra, A; Plevova, K; Ovesna, P; Radova, L; Doubek, M; Pavlova, S; Pospisilova, S; Bryja, V, 2018: Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia. HAEMATOLOGICA 103(2), p. 313 - 324, doi: 10.3324/haematol.2017.178699
• Zaprazna, K; Basu, A; Tom, N; Jha, V; Hodawadekar, S; Radova, L; Malcikova, J; Tichy, B; Pospisilova, S; Atchison, ML, 2018: Transcription factor YY1 can control AID-mediated mutagenesis in mice. EUROPEAN JOURNAL OF IMMUNOLOGY 48(2), p. 273 - 282, doi: 10.1002/eji.201747065
• Baliakas, P.; Mattsson, M.; Hadzidimitriou, A.; Minga, E.; Agathangelidis, A.; Sutton, L.; Scarfo, L.; Davis, Z.; Yan, X.; Plevova, K.; Sandberg, Y.; Vojdeman, F. J.; Tzenou, T.; Chu, C. C.; Veronese, S.; Mansouri, L.; Smedby, K. E.; Giudicelli, V.; Nguyen-Khac, F.; Panagiotidis, P.; Juliusson, G.; Anagnostopoulos, A.; Lefranc, M.; Trentin, L.; Catherwood, M.; Montillo, M.; Niemann, C. U.; Langerak, A. W.; Pospisilova, S.; Stavroyianni, N.; Chiorazzi, N.; Oscier, D.; Jelinek, D. F.; Shanafelt, T.; Darzentas, N.; Belessi, C.; Davi, F.; Ghia, P.; Rosenquist, R.; Stamatopoulos, K., 2018: No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy. HAEMATOLOGICA , doi: 10.3324/haematol.2017.182634
• Bencurova, P; Baloun, J; Hynst, J; Tichy, B; Pospisilova, S; Kubova, H; Brazdil, M, 2018: Dynamics of Microrna Expression during Early Onset Epileptogenesis. EPILEPSIA 59, p. S58 - S58
• Kozubik, KS; Radova, L; Pesova, M; Reblova, K; Trizuljak, J; Plevova, K; Fiamoli, V; Gumulec, J; Urbankova, H; Szotkowski, T; Mayer, J; Pospisilova, S; Doubek, M, 2018: C-terminal RUNX1 mutation in familial platelet disorder with predisposition to myeloid malignancies. INTERNATIONAL JOURNAL OF HEMATOLOGY 108(6), p. 652 - 657, doi: 10.1007/s12185-018-2514-3
• Cerna, K; Oppelt, J; Musilova, K; Seda, V;Pavlasova, K; Radova, L; Arigoni, M; Calogero, RA; Benes, V; Tbusek, M; Brychtova, Y; Doubek, M; Mayer, J; Pospisilova, S; Mraz, M, 2018: MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells. LEUKEMIA
• Larose, H; Mian, S; Nuglozeh, E; Fazaludeen, FMS; Elmouna, A; Ashankyty, I; Du, MQ; Hoefler, G; Pospisilova, S; Woessmann, W; Damm-Welk, C; Fedorova, A; Lamant, L; Schlederer, M; Merkel, O; Kenner, L; Turner, SD, 2018: Investigating the functional impact of single nucleotide variants in anaplastic large cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY 182, p. 41 - 42
• Tom, N; Tom, O; Malcikova, J; Pavlova, S; Kubesova, B; Rausch, T; Kolarik, M; Benes, V; Bystry, V; Pospisilova, S, 2018: ToTem: a tool for variant calling pipeline optimization. BMC BIOINFORMATICS 19, doi: 10.1186/s12859-018-2227-x
• Lobello, C; Bikos, V; Janikova, A; Pospisilova, S, 2018: The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability. CANCERS 10(3), doi: 10.3390/cancers10030064
• Malcikova, J; Tausch, E; Rossi, D; Sutton, LA; Soussi, T; Zenz, T; Kater, AP; Niemann, CU; Gonzalez, D; Davi, F; Diaz, MG; Moreno, C; Gaidano, G; Stamatopoulos, K; Rosenquist, R; Stilgenbauer, S; Ghia, P; Pospisilova, S, 2018: ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. LEUKEMIA 32(5), p. 1070 - 1080, doi: 10.1038/s41375-017-0007-7
• Janovska, P; Verner, J; Kohoutek, J; Bryjova, L; Gregorova, M; Dzimkova, M; Skabrahova, H; Radaszkiewicz, T; Ovesna, P; Blanarova, OV; Nemcova, T; Hoferova, Z; Vasickova, K; Smyckova, L; Egle, A; Pavlova, S; Poppova, L; Plevova, K; Pospisilova, S; Bryja, V, 2018: Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. BLOOD 131(11), p. 1206 - 1218, doi: 10.1182/blood-2017-05-786947

2017

• Kafkova, LR; Navrkalova, V; Jarosova, M; Loja, T; Chovancova, J; Kucerova, J; Kriegova, E; Prochazka, V; Novak, Z; Simkova, D; Pospisilova, S; Divoky, V, 2017: Ability to downregulate the level of cyclin-dependent kinase inhibitor p27(Kip1) after DNA damage is retained in chronic lymphocytic leukemia cells with functional ATM/p53 signaling pathway. LEUKEMIA & LYMPHOMA 58(1), p. 199 - 203, doi: 10.1080/10428194.2016.1187276
• Vardi, A; Vlachonikola, E; Karypidou, M; Stalika, E; Bikos, V; Gemenetzi, K; Maramis, C; Siorenta, A; Anagnostopoulos, A; Pospisilova, S; Maglaveras, N; Chouvarda, I; Stamatopoulos, K; Hadzidimitriou, A, 2017: Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements. LEUKEMIA 31(7), p. 1555 - 1561, doi: 10.1038/leu.2016.362
• Baliakas, P; Jeromin, S; Iskas, M; Puiggros, A; Plevova, K; Xochelli, A; Delgado, J; Kotaskova, J; Stalika, E; Abrisqueta, P; Durechova, K; Papaioannou, G; Collado, R; Doubek, M; Calasanz, MJ; Ruiz-Xiville, N; Moreno, C; Leeksma, AC; Anagnostopoulos, A; Ghia, P; Stavroyianni, N; Kater, AP; Espinet, B; Pospisilova, S; Athanasiadou, A; Stamatopoulos, K; Haferlach, C, 2017: CYTOGENETIC COMPLEXITY IN CHRONIC LYMPHOCYTIC LEUKEMIA: DEFINITIONS, ASSOCIATIONS WITH OTHER BIOMARKERS AND CLINICAL IMPACT; A RETROSPECTIVE STUDY ON BEHALF OF ERIC. HAEMATOLOGICA 102, p. 170 - 170
• Plevova, K; Malcikova, J; Pavlova, S; Kotaskova, J; Poppova, L; Smardova, J; Diviskova, E; Durechova, K; Oltova, A; Brychtova, Y; Panovska, A; Doubek, M; Pospisilova, S, 2017: BIALLELIC TP53 GENE MUTATIONS DUE TO COPY-NEUTRAL LOSS OF HETEROZYGOSITY AND MONOALLELIC MUTATIONS IN ABSENCE OF 17P DELETION OCCUR IN CLL WITH COMPARABLE FREQUENCY. HAEMATOLOGICA 102, p. 65 - 66
• Pavlasova, G; Borsky, M; Svobodova, V; Musilova, K; Cerna, K; Seda, V; Osickova, J; Brychtova, Y; Doubek, M; Pospisilova, S; Mayer, J; Mraz, M, 2017: BCR SIGNALLING PROFICIENT CHRONIC LYMPHOCYTIC LEUKAEMIA B CELLS ARE PRONE TO RITUXIMAB MEDIATED ELIMINATION IN VIVO. HAEMATOLOGICA 102, p. 412 - 412
• Ledererova, A; Kozlova, V; Vakulova, V; Doubek, M; Mayer, J; Pospisilova, S; Smida, M, 2017: B CELLS RESISTANT TO CD20 MONOCLONAL ANTIBODIES DISPLAY SPECIFIC ALTERATIONS IN GENE EXPRESSION PROFILE. HAEMATOLOGICA 102, p. 709 - 709
• Leroy, B; Ballinger, ML; Baran-Marszak, F; Bond, GL; Braithwaite, A; Concin, N; Donehower, LA; El-Deiry, WS; Fenaux, P; Gaidano, G; Langerod, A; Hellstrom-Lindberg, E; Iggo, R; Lehmann-Che, J; Mai, PL; Malkin, D; Moll, UM; Myers, JN; Nichols, KE; Pospisilova, S; Ashton-Prolla, P; Rossi, D; Savage, SA; Strong, LC; Tonin, PN; Zeillinger, R; Zenz, T; Fraumeni, JF; Taschner, PEM; Hainaut, P; Soussi, T, 2017: Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. CANCER RESEARCH 77(6), p. 1250 - 1260, doi: 10.1158/0008-5472.CAN-16-2179
• Plesingerova, H; Librova, Z; Plevova, K; Libra, A; Tichy, B; Francova, HS; Vrbacky, F; Smolej, L; Mayer, J; Bryja, V; Doubek, M; Pospisilova, S, 2017: COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status. LEUKEMIA & LYMPHOMA 58(1), p. 70 - 79, doi: 10.1080/10428194.2016.1180690
• Kotaskova, J; Pavlova, S; Plevova, K; Malcikova, J; Stehlikova, O; Poppova, L; Kockova, H; Doubek, M; Bryja, V; Pospisilova, S, 2017: TREATMENT WITH BCR INHIBITORS INCREASES ROR1 EXPRESSION IN CLL CELLS. HAEMATOLOGICA 102, p. 414 - 414
• Janovska, P; Verner, J; Kohoutek, J; Bryjoval, L; Dzimkova, M; Skabrahova, H; Radaszkiewicz, T; Nemcova, T; Hoferova, Z; Vasickova, K; Smyckova, L; Gregorova, M; Egle, A; Pavlova, S; Poppova, L; Pospisilova, S; Bryja, V, 2017: Casein Kinase 1 delta/epsilon inhibition blocks CLL chemotaxis and delays leukemia onset in the E mu-TCL1 mouse model of chronic lymphocytic leukemia. LEUKEMIA & LYMPHOMA 58, p. 210 - 211
• Sutton, LA; Cortese, D; Ljungstrom, V; Plevova, K; Rossi, D; Stalika, E; Agathangelidis, A; Scarfo, L; Muggen, AF; Langerak, AW; Pospisilova, S; Davi, F; Ghia, P; Stamatopoulos, K; Brandell, RR, 2017: Transcriptome sequencing provides novel insights into the biology of chronic lymphocytic leukemia: focus on major stereotyped subsets. LEUKEMIA & LYMPHOMA 58, p. 220 - 221
• Malcikova, J; Kotaskova, J; Tom, N; Pal, K; Panovska, A; Brychtova, Y; Doubek, M; Pavlova, S; Pospisilova, S, 2017: Tracking low-burden TP53-mutated subclones during CLL treatment and remission using ROR1 separation. LEUKEMIA & LYMPHOMA 58, p. 162 - 163
• Baumann, T; Doubek, M; Kotaskova, J; Molica, S; Mozas, P; Rivas-Delgado, A; Morabito, F; Pospisilova, S; Delgado, J; Montserrat, E, 2017: The Barcelona-Brno Biomarkers-Only (IGHV mutational status and FISH cytogenetics) prognostic model for chronic lymphocytic leukemia. LEUKEMIA & LYMPHOMA 58, p. 147 - 149
• Mraz, M; Cerna, K; Oppelt, J; Seda, V; Musilova, K; Pavlasova, G; Mayer, J; Pospisilova, S, 2017: MicroRNA induced by DNA damage response regulates the expression of FOXP1 and therapy response in CLL. LEUKEMIA & LYMPHOMA 58, p. 73 - 74
• Baliakas, P; Jeronim, S; Iskas, M; Puiggros, A; Plevova, K; Xochelli, A; Delgado, J; Kotaskova, J; Stalika, E; Costa, PA; Durechova, K; Papaioannou, G; Collado, R; Doubek, M; Calasanz, MJ; Ruiz-Xiville, N; Moreno, C; Anagnostopoulos, A; Stavroyianni, N; Kater, A; Espinet, B; Pospisilova, S; Athanasiadou, A; Stamatopoulos, K; Haferlach, C, 2017: Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations with other bio-markers and clinical impact. LEUKEMIA & LYMPHOMA 58, p. 65 - 66
• Delgado, J; Doubek, M; Baumann, T; Kotaskova, J; Molica, S; Mozas, P; Rivas-Delgado, A.; Morabito, F; Pospisilova, S; Montserrat, E, 2017: Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. AMERICAN JOURNAL OF HEMATOLOGY , doi: 10.1002/ajh.24660

2016

• Kubesova, B; Pavlova, S; Malcikova, J; Kabathova, J; Radova, L; Tom, N; Tichy, B; Plevova, K; Kantorova, B; Fiedorova, K; Kissova, J; Gisslinger, B; Gisslinger, H; Mayer, J; Kralovics, R; Pospisilova, S; Doubek, M, 2016: Low-Burden TP53 Mutations Occur in Chronic Phase of Myeloproliferative Neoplasms Regardless of Hydroxyurea Administration, Disease Type, and JAK2 Status. BLOOD 128(22)
• Bikos, V; Karypidou, M; Stalika, E; Baliakas, P; Xochelli, A; Sutton, LA; Papadopoulos, G; Agathangelidis, A; Papadopoulou, E; Davis, Z; Algara, P; Kanellis, G; Traverse-Glehen, A; Mollejo, M; Anagnostopoulos, A; Ponzoni, M; Gonzalez, D; Pospisilova, S; Matutes, E; Piris, MA; Papadaki, T; Ghia, P; Rosenquist, R; Oscier, D; Darzentas, N; Tzovaras, D; Belessi, C; Hadzidimitriou, A; Stamatopoulos, K, 2016: An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors. CLINICAL CANCER RESEARCH 22(8), p. 2032 - 2040, doi: 10.1158/1078-0432.CCR-15-1170
• Baliakas, P; Puiggros, A; Xochelli, A; Sutton, LA; Nguyen-Khac, F; Gardiner, A; Plevova, K; Minga, E; Hadzidimitriou, A; Walewska, R; McCarthy, H; Ortega, M; Collado, R; Gonzalez, T; Granada, I; Luno, E; Kotaskova, J; Moysiadis, T; Davis, Z; Stavroyianni, N; Anagnostopoulos, A; Strefford, JC; Pospisilova, S; Davi, F; Athanasiadou, A; Rosenquist, R; Oscier, D; Espinet, B; Stamatopoulos, K, 2016: Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference. HAEMATOLOGICA 101(7), p. 299 - 302, doi: 10.3324/haematol.2015.140202
• Zaprazna, K; Malcikova, J; Tom, N; Radova, L; Trbusek, M; Atchison, M; Pospisilova, S, 2016: ACTIVATION INDUCED DEAMINASE SPLICE VARIANTS EXPRESSED IN B CELL LEUKEMIA AND LYMPHOMA DO NOT RETAIN THEIR CATALYTIC ACTIVITY. HAEMATOLOGICA 101, p. 429 - 430
• Mareckov, A; Malcikova, J; Tom, N; Pal, K; Salek, D; Pospisilova, S; Trbusek, M, 2016: ATM GENE MUTATIONS REPRESENT A HALLMARK OF MANTLE CELL LYMPHOMA BUT DO NOT IMPACT PATIENTS´ SURVIVAL. HAEMATOLOGICA 101, p. 271 - 271
• Poppova, L; Janovska, P; Plevova, K; Radova, L; Plesingerova, H; Borsky, M; Kotaskova, J; Kantorova, B; Hlozkova, M; Figulova, J; Brychtova, Y; Doubek, M; Kozubik, A; Pospisilova, S; Pavlova, S; Bryja, V, 2016: DECREASED EXPRESSION OF WNT3, A CANONICAL WNT PATHWAY LIGAND, IS FREQUENT IN CHRONIC LYMPHOCYTIC LEUKEMIA PROGRESSION AND IDENTIFIES PATIENTS WITH SHORT TREATMENT-FREE SURVIVAL IN MUTATED IGHV SUBSET. HAEMATOLOGICA 101, p. 423 - 424
• Baliakas, P; Mattsson, M; Hadzidimitriou, A; Minga, E; Agathangelidis, A; Sutton, LA; Scarfo, L; Davis, Z; Yan, XJ; Plevova, K; Sandberg, Y; Vojdeman, FJ; Tzenou, T; Chu, CC; Veroneze, S; Mansouri, L; Smedby, KE; Giudicelli, V; Nguyen-Khac, F; Panagiotidis, P; Juliusson, G; Anagnostopoulos, A; Lefranc, MP; Trentin, L; Catherwood, M; Montillo, M; Niemann, CU; Langerak, AW; Pospisilova, S; Stavroyianni, N; Chiorazzi, N; Oscier, D; Jelinek, DF; Shanafelt, T; Darzentas, N; Belessi, C; Davi, F; Ghia, P; Rosenquist, R; Stamatopoulos, K, 2016: NO IMPROVEMENT IN LONG-TERM OVERALL SURVIVAL AFTER THE INTRODUCTION OF CHEMO(IMMUNO)THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS BELONGING TO STEREOTYPED SUBSET #2. HAEMATOLOGICA 101, p. 231 - 231
• Pospisilova, S; Sutton, LA; Malcikova, J; Tausch, E; Rossi, D; Montserrat, E; Moreno, C; Stamatopoulos, K; Gaidano, G; Rosenquist, R; Ghia, P, 2016: Innovation In the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?. HAEMATOLOGICA 101(3), p. 263 - 265, doi: 10.3324/haematol.2015.139246
• Pavlasova, G; Borsky, M; Seda, V; Cerna, K; Osickova, J; Doubek, M; Mayer, J; Calogero, R; Pospisilova, S; Davids, M; Brown, J; Mraz, M, 2016: IBRUTINIB INHIBITS CD20 UP-REGULATION ON CLL B CELLS MEDIATED BY THE CXCR4/SDF-1 AXIS. HAEMATOLOGICA 101, p. 47 - 47
• Turchaninova, MA; Davydov, A; Britanova, OV; Shugay, M; Bikos, V; Egorov, ES; Kirgizova, VI; Merzlyak, EM; Staroverov, DB; Bolotin, DA; Mamedov, IZ; Izraelson, M; Logacheva, MD; Kladova, O; Plevova, K; Pospisilova, S; Chudakov, DM, 2016: High-quality full-length immunoglobulin profiling with unique molecular barcoding. NATURE PROTOCOLS 11(9), p. 1599 - 1616, doi: 10.1038/nprot.2016.093
• Kopparapu, PK; Bhoi, S; Mansouri, L; Arabanian, LS; Plevova, K; Pospisilova, S; Wasik, AM; Croci, GA; Sander, B; Paulli, M; Rosenquist, R; Kanduri, M, 2016: Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression. EPIGENETICS 11(5), p. 335 - 343, doi: 10.1080/15592294.2016.1164375
• Sutton, LA; Young, E; Baliakas, P; Hadzidimitriou, A; Moysiadis, T; Plevova, K; Rossi, D; Kminkova, J; Stalika, E; Pedersen, LB; Malcikova, J; Agathangelidis, A; Davis, Z; Mansouri, L; Scarfo, L; Boudjoghra, M; Navarro, A; Muggen, AF; Yan, XJ; Nguyen-Khac, F; Larrayoz, M; Panagiotidis, P; Chiorazzi, N; Niemann, CU; Belessi, C; Campo, E; Strefford, JC; Langerak, AW; Oscier, D; Gaidano, G; Pospisilova, S; Davi, F; Ghia, P; Stamatopoulos, K; Rosenquist, R, 2016: Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. HAEMATOLOGICA 101(8), p. 959 - 967, doi: 10.3324/haematol.2016.141812
• Janovska, P; Poppova, L; Plevova, K; Plesingerova, H; Behal, M; Kaucka, M; Ovesna, P; Hlozkova, M; Borsky, M; Stehlikova, O; Brychtova, Y; Doubek, M; Machalova, M; Baskar, S; Kozubik, A; Pospisilova, S; Pavlova, S; Bryja, V, 2016: Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia. CLINICAL CANCER RESEARCH 22(2), p. 459 - 469, doi: 10.1158/1078-0432.CCR-15-0154
• Poppova, L; Janovska, P; Plevova, K; Radova, L; Plesingerova, H; Borsky, M; Kotaskova, J; Kantorova, B; Hlozkova, M; Figulova, J; Brychtova, Y; Machalova, M; Urik, M; Doubek, M; Kozubik, A; Pospisilova, S; Pavlova, S; Bryja, V, 2016: Decreased WNT3 expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated IGHV. BRITISH JOURNAL OF HAEMATOLOGY 175(5), p. 851 - 859, doi: 10.1111/bjh.14312
• Rawstron, AC; Fazi, C; Agathangelidis, A; Villamor, N; Letestu, R; Nomdedeu, J; Palacio, C; Stehlikova, O; Kreuzer, KA; Liptrot, S; O´Brien, D; de Tute, RM; Marinov, I; Hauwel, M; Spacek, M; Dobber, J; Kater, AP; Gambell, P; Soosapilla, A; Lozanski, G; Brachtl, G; Lin, K; Boysen, J; Hanson, C; Jorgensen, JL; Stetler-Stevenson, M; Yuan, C; Broome, HE; Rassenti, L; Craig, F; Delgado, J; Moreno, C; Bosch, F; Egle, A; Doubek, M; Pospisilova, S; Mulligan, S; Westerman, D; Sanders, CM; Emerson, R; Robins, HS; Kirsch, I; Shanafelt, T; Pettitt, A; Kipps, TJ; Wierda, WG; Cymbalista, F; Hallek, M; Hillmen, P; Montserrat, E; Ghia, P, 2016: A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. LEUKEMIA 30(4), p. 929 - 936, doi: 10.1038/leu.2015.313

2015

• Vardi, A; Stalika, E; Gkoufas, A; Karipidou, M; Maramis, C; Bikos, V; Pospisilova, S; Anagnostopoulos, A; Maglaveras, N; Chouvarda, I; Stamatopoulos, K; Hadzidimitriou, A, 2015: HIGH-THROUGHPUT T-CELL RECEPTOR GENE REPERTOIRE PROFILING IN CHRONIC LYMPHOCYTIC LEUKEMIA SUBSET #4: FURTHER EVIDENCE OF ANTIGENIC STIMULATION. HAEMATOLOGICA 100, p. 11 - 12
• Ljungstrom, V; Cortese, D; Young, E; Pandzic, T; Mansouri, L; Plevova, K; Sutton, LA; Stavroyianni, N; Agathangelidis, A; Rossi, D; Hoglund, M; Oscier, D; Gaidano, G; Davi, F; Pott, C; Trentin, L; Pospisilova, S; Ghia, P; Stamatopoulos, K; Sjoblom, T; Rosenquist, R, 2015: DISSECTING RESISTANCE MECHANISMS IN CHRONIC LYMPHOCYTIC LEUKEMIA USING WHOLE-EXOME SEQUENCING: IMPACT OF RECURRENT RPS15 MUTATIONS ON P53 DYSREGULATION. HAEMATOLOGICA 100, p. 10 - 11
• Navrkalova, V; Kafkova, LR; Divoky, V; Pospisilova, S, 2015: Oxidative stress as a therapeutic perspective for ATM-deficient chronic lymphocytic leukemia patients. HAEMATOLOGICA 100(8), p. 994 - 996, doi: 10.3324/haematol.2015.130260
• Pavlasova, G; Seda, V; Borsky, M; Cerna, K; Osickova, J; Mayer, J; Pospisilova, S; Davids, MS; Brown, JR; Mraz, M, 2015: Microenvironmental Interactions up-Regulate CD20 Expression in CLL B Cells through the CXCR4/SDF-1 Axis: Implications for CD20-Targeting Antibodies and the Use of BCR-Inhibitors in Combination. BLOOD 126(23)
• Noerenberg, D; Young, E; Ljungstrom, V; Mansouri, L; Plevova, K; Baliakas, P; Blakemore, S; Rossi, D; Clifford, R; Navrkalova, V; Sutton, LA; Smedby, KE; Juliusson, G; Belessi, C; Panagiotidis, P; Chiorazzi, N; Davi, F; Langerak, AW; Schuh, A; Gaidano, G; Strefford, JC; Ghia, P; Stamatopoulos, K; Pospisilova, S; Zenz, T; Rosenquist, R; Damm, F, 2015: EGR2 Mutations in Chronic Lymphocytic Leukemia: A New Bad Player. BLOOD 126(23)
• Kantorova, B; Malcikova, J; Brazdilova, K; Borsky, M; Plevova, K; Smardova, J; Trbusek, M; Brychtova, Y; Doubek, M; Mayer, J; Pospisilova, S, 2015: Single Cell Analysis Proves the Coexistence of NOTCH1 and TP53 Mutations within the Same Cancer Cells in Patients with Chronic Lymphocytic Leukemia. BLOOD 126(23)
• Chatzilari, E; Baliakas, P; Xochelli, A; Maronidis, A; Vardi, A; Mattsson, M; Larsson, K; Douka, V; Iskas, M; Karavalakis, G; Papalexandri, A; Niemann, C; Montillo, M; Anagnostopoulos, A; Oscier, D; Pospisilova, S; Davi, F; Stavroyianni, N; Ghia, P; Hadzidimitriou, A; Rosenquist, R; Nikolopoulos, S; Stamatopoulos, K; Kompatsiaris, Y, 2015: Personalized Modeling of Disease Evolution in CLL: Does Statistical Significance Translate into Predictive Accuracy?. BLOOD 126(23)
• Agathangelidis, A; Bystry, V; Hadzidimitriou, A; Sutton, LA; Minga, E; Kienle, D; Davis, Z; Yan, XJ; Shanafelt, T; Boudjogra, M; Plevova, K; Gounari, M; Xochelli, A; Navarro, A; Chatzouli, M; Pedersen, LB; Baliakas, P; Scarfo, L; Rossi, D; Veronese, S; Facco, M; Bikos, V; Karan-Djurasevic, T; Pavlovic, S; Mansouri, L; Poiron, C; Chu, CC; Stalika, E; Giudicelli, V; Panagiotidis, P; Sudarikov, A; Anagnostopoulos, A; Trentin, L; Catherwood, M; Montillo, M; Gaidano, G; Campo, E; Geisler, CH; Langerak, AW; Pospisilova, S; Lefranc, MP; Chiorazzi, N; Oscier, D; Jelinek, DF; Stilgenbauer, S; Belessi, C; Davi, F; Rosenquist, R; Ghia, P; Darzentas, N; Stamatopoulos, K, 2015: HIGHER-ORDER IMMUNOGLOBULIN SEQUENCE RELATIONS FOR MAJOR SUBSETS OF CHRONIC LYMPHOCYTIC LEUKEMIA: UNIQUENESS VERSUS EQUIVALENCE. HAEMATOLOGICA 100, p. 47 - 48
• Plesingerova, H; Janovska, P; Poppova, L; Shaik, A; Jurcickova, Z; Libra, A; Plevova, K; Machac, J; Slapak, I; Pavlova, S; Ovesna, P; Kotaskova, J; Doubek, M; Pospisilova, S; Bryja, V, 2015: UPREGULATED COBLL1 IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) PATIENTS WITH UNMUTATED IGHV IDENTIFIES A COHORT WITH INFERIOR PROGNOSIS. HAEMATOLOGICA 100, p. 50 - 50
• Tom, N; Malcikova, J; Radova, L; Kantorova, B; Pardy, F; Pavlova, S; Pal, K; Mraz, M; Tichy, B; Doubek, M; Brychtova, Y; Plevova, K; Mayer, J; Trbusek, M; Pospisilova, S, 2015: MUTATIONS IN THE TP53 GENE SHOW FEATURES OF SOMATIC HYPERMUTATION PROCESS WITH PROMINENT DIFFERENCE BETWEEN IGHV MUTATED AND UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA. HAEMATOLOGICA 100, p. 224 - 225
• Baliakas, P; Hadzidimitriou, A; Mattsson, M; Xochelli, A; Sutton, LA; Minga, E; Scarfo, L; Rossi, D; Davis, Z; Agathangelidis, A; Villamor, N; Parker, H; Kotaskova, J; Stalika, E; Plevova, K; Mansouri, L; Cortese, D; Lopez, AN; Delgado, J; Larrayoz, M; Anagnostopoulos, A; Belessi, C; Smedby, KE; Juliusson, G; Strefford, JC; Pospisilova, S; Oscier, D; Gaidano, G; Campo, E; Ghia, P; Rosenquist, R; Stamatopoulos, K, 2015: REFINING PROGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH SOMATICALLY HYPERMUTATED B-CELL RECEPTORS: A NOVEL PROGNOSTIC INDEX ON BEHALF OF THE EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC). HAEMATOLOGICA 100, p. 52 - 52
• Brazdilova, K; Plevova, K; Francova, HS; Kockova, H; Chmelikova, M; Borsky, M; Burckova, K; Kantorova, B; Tichy, B; Skabrahova, H; Brychtova, Y; Mayer, J; Doubek, M; Pospisilova, S, 2015: Single Cell Analysis of IG Genes in CLL: Cases with Multiple IGH Rearrangements Are Constituted of Several Independent Clones Even When Indistinguishable By Flow Cytometry. BLOOD 126(23)
• Baliakas, P; Hadzidimitriou, A; Agathangelidis, A; Rossi, D; Sutton, LA; Kminkova, J; Scarfo, L; Pospisilova, S; Gaidano, G; Stamatopoulos, K; Ghia, P; Rosenquist, R, 2015: Prognostic relevance of MYD88 mutations in CLL: the jury is still out. BLOOD 126(8), p. 1043 - 1044, doi: 10.1182/blood-2015-05-648634
• Zadrazilova, I; Pospisilova, S; Pauk, K; Imramovsky, A; Vinsova, J; Cizek, A; Jampilek, J, 2015: In Vitro Bactericidal Activity of 4-and 5-Chloro-2-hydroxy-N-[1-oxo-1-(phenylamino)alkan-2-yl]benzamides against MRSA. BIOMED RESEARCH INTERNATIONAL , doi: 10.1155/2015/349534
• Xochelli, A; Bikos, V; Polychronidou, E; Agathangelidis, A; Charlotte, F; Moschonas, P; Davis, Z; Colombo, M; Roumelioti, M; Sutton, LA; Groenen, P; Boudjoghra, M; Algara, P; Traverse-Glehen, A; Ferrer, A; Stalika, E; Karypidou, M; Kanellis, G; Kalpadakis, C; Mollejo, M; Pangalis, G; Vlamos, P; Amini, RM; Pospisilova, S; Gonzalez, D; Ponzoni, M; Anagnostopoulos, A; Giudicelli, V; Lefranc, MP; Espinet, B; Panagiotidis, P; Piris, MA; Du, M; Rosenquist, R; Papadaki, T; Belessi, C; Ferrarini, M; Oscier, D; Tzovaras, D; Ghia, P; Davi, F; Hadzidimitriou, A; Stamatopoulos, K, 2015: Unique Versus Common: Disease-Biased Immunoglobulin Gene Repertoires Along with Public Antigen Receptor Stereotypes in Marginal Zone B-Cell Lymphoproliferations. BLOOD 126(23)
• Vardi, A; Karipidou, M; Gemenetzi, A; Vlachonikola, E; Bikos, V; Stalika, E; Koravou, E; Maramis, C; Siorenta, A; Anagnostopoulos, A; Pospisilova, S; Maglaveras, N; Chouvarda, I; Stamatopoulos, K; Hadzidimitriou, A, 2015: Next Generation Sequence Immunoprofiling of the T-Cell Repertoire in Chronic Lymphocytic Leukemia Supports Selection By Shared Antigenic Elements. BLOOD 126(23)
• Navrkalova, V; Young, E; Baliakas, P; Radova, L; Plevova, K; Sutton, LA; Mansouri, L; Ljungstrom, V; Ntoufa, S; Davis, Z; Juliusson, G; Smedby, KE; Belessi, C; Panagiotidis, P; Davi, F; Langerak, AW; Ghia, P; Strefford, JC; Oscier, DG; Stamatopoulos, K; Pospisilova, S; Rosenquist, R; Trbusek, M, 2015: ATM Mutations in Major Stereotyped CLL Subsets: Enrichment in Subset #2 is Associated with Unfavourable Outcome. BLOOD 126(23)
• Baliakas, P; Puiggros, A; Xochelli, A; Sutton, LA; Nguyen-Khac, F; Gardiner, A; Plevova, K; Ortega, M; Collado, R; Gonzalez, T; Granada, I; Luno, E; Kotaskova, J; Davis, Z; Anagnostopoulos, A; Strefford, J; Pospisilova, S; Davi, F; Athanasiadou, A; Rosenquist, R; Oscier, D; Sola, BE; Stamatopoulos, K, 2015: ADDITIONAL TRISOMIES AMONGST PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA CARRYING TRISOMY 12: THE PARTNER CHROMOSOME MAKES A DIFFERENCE. HAEMATOLOGICA 100, p. 224 - 224
• Young, E; Norenberg, D; Ljungstrom, V; Mansouri, L; Plevova, K; Baliakas, P; Rossi, D; Navrkalova, V; Sutton, LA; Smedby, KE; Juliusson, G; Belessi, C; Panagiotidis, P; Chiorazzi, N; Davi, F; Langerak, AW; Gaidano, G; Ghia, P; Stamatopoulos, K; Pospisilova, S; Zenz, T; Rosenquist, R; Damm, F, 2015: EGR2 mutations in chronic lymphocytic leukemia- a new bad player?. LEUKEMIA & LYMPHOMA 56, p. 83 - 85
• Pavlasova, G; Borsky, M; Seda, V; Cerna, K; Osickova, J; Mayer, J; Pospisilova, S; Davids, M; Brown, J; Mraz, M, 2015: Microenvironmental interactions up-regulate CD20 expression in CLL B cells, but confer resistance to rituximab. LEUKEMIA & LYMPHOMA 56, p. 76 - 77
• Verner, J; Trbusek, M; Chovancova, J; Jaskova, Z; Moulis, M; Folber, F; Halouzka, R; Mayer, J; Pospisilova, S; Doubek, M, 2015: NOD/SCID IL2R gamma-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell lines. LEUKEMIA & LYMPHOMA 56(11), p. 3198 - 3206, doi: 10.3109/10428194.2015.1034701
• Kotaskova, J; Malcikova, J; Diviskova, E; Pavlova, S; Mejstrikova, S; Vranova, V; Plevova, K; Plesingerova, H; Doubek, M; Mayer, J; Pospisilova, S, 2015: 13Q DELETION IS PREDOMINANT CYTOGENETIC ABERRATION NEWLY AQUIRED DURING CHRONIC LYMPHOCYTIC LEUKEMIA COURSE IRRESPECTIVE OF DISEASE ACTIVITY AND TREATMENT STATUS. HAEMATOLOGICA 100, p. 417 - 418

2014

• Janikova, A; Mareckova, A; Baumeisterova, A; Krejci, M; Supikova, J; Salek, D; Horky, O; Tichy, B; Hanke, I; Pospisilova, S; Moulis, M; Mayer, J, 2014: Transmission of t(11;14)-positive cells by allogeneic stem cell transplant: 10-year journey to mantle cell lymphoma. LEUKEMIA & LYMPHOMA 55(8), p. 1935 - 1938, doi: 10.3109/10428194.2013.858150
• Benner, A; Mansouri, L; Rossi, D; Majid, A; Willander, K; Parker, A; Bond, G; Pavlova, S; Nuckel, H; Merkel, O; Ghia, P; Montserrat, E; Kaderi, MA; Rosenquist, R; Gaidano, G; Dyer, MJS; Soderkvist, P; Linderholm, M; Oscier, D; Tvaruzkova, Z; Pospisilova, , 2014: MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. HAEMATOLOGICA 99(8), p. 1285 - 1291, doi: 10.3324/haematol.2013.101170
• Sebejova, L; Borsky, M; Jaskova, Z; Potesil, D; Navrkalova, V; Malcikova, J; Sramek, M; Doubek, M; Loja, T; Pospisilova, S; Mayer, J; Trbusek, M, 2014: Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab. EXPERIMENTAL HEMATOLOGY 42(10), p. 867 - 874, doi: 10.1016/j.exphem.2014.06.003
• te Raa, GD; Malcikova, J; Mraz, M; Trbusek, M; Le Garff-Tavernier, M; Merle-Beral, H; Greil, R; Merkel, O; Pospisilova, S; Lin, K; Pettitt, AR; Stankovic, T; van Oers, MH; Eldering, E; Stilgenbauer, S; Zenz, T; Kater, AP, 2014: Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach. BRITISH JOURNAL OF HAEMATOLOGY 167(4), p. 565 - 569, doi: 10.1111/bjh.13006
• Malcikova, J; Stalika, E; Davis, Z; Plevova, K; Trbusek, M; Mansouri, L; Scarfo, L; Baliakas, P; Gardiner, A; Sutton, LA; Francova, HS; Agathangelidis, A; Anagnostopoulos, A; Tracy, I; Makris, A; Smardova, J; Ghia, P; Belessi, C; Gonzalez, D; Rosenquist, , 2014: The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors. BRITISH JOURNAL OF HAEMATOLOGY 166(4), p. 621 - 625, doi: 10.1111/bjh.12893
• Robesova, B; Bajerova, M; Liskova, K; Skrickova, J; Tomiskova, M; Pospisilova, S; Mayer, J; Dvorakova, D, 2014: TaqMan based real time PCR assay targeting EML4-ALK fusion transcripts in NSCLC. LUNG CANCER 85(1), p. 25 - 30, doi: 10.1016/j.lungcan.2014.04.002
• Eldering, E; te Raa, D; Derks, I; Navrkalova, V; Skowronska, A; Oldreive, C; Moerland, P; Malcikova, J; Trbusek, M; Hullein, J; Jethwa, A; Zenz, T; Pospisilova, S; Stankovic, T; van Oers, M; Kater, A, 2014: SF3B1 MUTATIONS IN CLL ARE ASSOCIATED WITH A DEFECTIVE DNA DAMAGE RESPONSE. HAEMATOLOGICA 99, p. 315 - 316
• Sutton, LA; Ljungstrom, V; Mansouri, L; Young, E; Cortese, D; Navrkalova, V; Malcikova, J; Muggen, AF; Trbusek, M; Davi, F; Belessi, C; Langerak, AW; Ghia, P; Pospisilova, S; Stamatopoulos, K; Rosenquist, R, 2014: TARGETED NEXT-GENERATION SEQUENCING FOR MUTATIONAL SCREENING IN CHRONIC LYMPHOCYTIC LEUKEMIA: A HIGH-THROUGHPUT YET TAILORED APPROACH WILL FACILITATE IMPLEMENTATION WITHIN A CLINICAL SETTING. HAEMATOLOGICA 99, p. 313 - 314
• Verner, J; Trbusek, M; Chovancova, J; Skabrahova, H; Jaskova, Z; Moulis, M; Folber, F; Halouzka, R; Mayer, J; Pospisilova, S; Doubek, M, 2014: NOD/SCID GAMMA XENOGRAFT MODEL OF B-CELL MALIGNANCIES USING TP53-AND/OR ATM-DEFICIENT CELL LINES. HAEMATOLOGICA 99, p. 312 - 313
• Navrkalova, V; Mareckova, A; Janikova, A; Doubek, M; Mayer, J; Pospisilova, S; Trbusek, M, 2014: INCORPORATION OF NEXT-GENERATION SEQUENCING INTO ATM GENE ANALYSIS IN PATIENTS WITH CLL AND MCL. HAEMATOLOGICA 99, p. 312 - 312
• Xochelli, A; Agathangelidis, A; Kavakiotis, I; Minga, E; Sutton, LA; Baliakas, P; Chouvarda, I; Giudicelli, V; Vlahavas, I; Maglaveras, N; Bonello, L; Trentin, L; Montillo, M; Panagiotidis, P; Geisler, C; Langerak, AW; Pospisilova, S; Jelinek, DF; Oscier,, 2014: IMMUNOGLOBULIN HEAVY VARIABLE GENES AND ALLELES: NEW ENTITIES, NEW NAMES AND IMPLICATIONS FOR RESEARCH AND PROGNOSTICATION IN CLL. HAEMATOLOGICA 99, p. 49 - 49
• Baliakas, P; Hadzidimitriou, A; Sutton, LA; Minga, E; Agathangelidis, A; Tsanousa, A; Scarfo, L; Davis, Z; Yan, XJ; Shanafelt, T; Plevova, K; Sandberg, Y; Vojdeman, FJ; Boudjogra, M; Tzenou, T; Chatzouli, M; Chu, CC; Veronese, S; Gardiner, A; Mansouri, L;, 2014: NOT ALL IGHV3-21 CLL ARE EQUAL: SUBSET #2 DISPLAYS A DISTINCTIVE CLINICOBIOLOGICAL PROFILE WITH REMARKABLE SIMILARITIES TO SUBSET #169, ITS CLOSE IMMUNOGENETIC RELATIVE. HAEMATOLOGICA 99, p. 48 - 49
• Cerna, K; Oppelt, J; Radova, L; Pardy, F; Tom, N; Musilova, K; Malcikova, J; Plevova, K; Tichy, B; Brychtova, Y; Doubek, M; Trbusek, M; Koca, J; Calogero, R; Mayer, J; Pospisilova, S; Mraz, M, 2014: BIOLOGICAL AND CLINICAL RELEVANCE OF MIRNAS INDUCED IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS DURING ADMINISTRATION OF THERAPY IN VIVO AND IN VITRO. HAEMATOLOGICA 99, p. 41 - 42
• Plesingerova, H; Janovska, P; Shaik, A; Poppova, L; Libra, A; Plevova, K; Machac, J; Slapak, I; Pavlova, S; Pospisilova, S; Bryja, V, 2014: HIGH LEVEL OF COBLL1, A NOVEL ROR1 BINDING PARTNER, IDENTIFIES CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WITH MUTATED IGHV. HAEMATOLOGICA 99, p. 39 - 39
• Doubek, M; Srovnal, J; Plevova, K; Trizuljak, J; Brychtova, Y; Semerad, L; Letalova, E; Benedikova, A; Mayer, J; Hajduch, M; Pospisilova, S, 2014: ANALYSIS OF MERKEL CELL POLYOMAVIRUS PROGNOSTIC SIGNIFICANCE IN CHRONIC LYMPHOCYTIC LEUKEMIA. HAEMATOLOGICA 99, p. 325 - 325
• Shugay, M; Britanova, OV; Merzlyak, EM; Turchaninova, MA; Mamedov, IZ; Tuganbaev, TR; Bolotin, DA; Staroverov, DB; Putintseva, EV; Plevova, K; Linnemann, C; Shagin, D; Pospisilova, S; Lukyanov, S; Schumacher, TN; Chudakov, DM, 2014: Towards error-free profiling of immune repertoires. NATURE METHODS 11(6), p. 653 - +, doi: 10.1038/NMETH.2960
• Malcikova, J; Pavlova, S; Kozubik, KS; Pospisilova, S, 2014: TP53 Mutation Analysis in Clinical Practice: Lessons From Chronic Lymphocytic Leukemia. HUMAN MUTATION 35(6), p. 663 - 671, doi: 10.1002/humu.22508
• Brejcha, M; Stoklasova, M; Brychtova, Y; Panovska, A; Stepanovska, K; Vankova, G; Plevova, K; Oltova, A; Horka, K; Pospisilova, S; Mayer, J; Doubek, M, 2014: Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: A prospective analysis. LEUKEMIA RESEARCH 38(2), p. 170 - 175, doi: 10.1016/j.leukres.2013.10.019
• Plevova, K; Francova, HS; Burckova, K; Brychtova, Y; Doubek, M; Pavlova, S; Malcikova, J; Mayer, J; Tichy, B; Pospisilova, S, 2014: Multiple productive immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukemia are mostly derived from independent clones. HAEMATOLOGICA 99(2), p. 329 - 338, doi: 10.3324/haematol.2013.087593
• Polanska, E; Pospisilova, S; Stros, M, 2014: Binding of Histone H1 to DNA Is Differentially Modulated by Redox State of HMGB1. PLOS ONE 9(2), doi: 10.1371/journal.pone.0089070
• Baliakas, P; Iskas, M; Gardiner, A; Davis, Z; Plevova, K; Florence, NK; Malcikova, J; Anagnostopoulos, A; Glide, S; Mould, S; Stepanovska, K; Brejcha, M; Belessi, C; Davi, F; Pospisilova, S; Athanasiadou, A; Stamatopoulos, K; Oscier, D, 2014: Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: A systematic reappraisal of classic cytogenetic data. AMERICAN JOURNAL OF HEMATOLOGY 89(3), p. 249 - 255, doi: 10.1002/ajh.23618
• Stehlikova, O; Chovancova, J; Tichy, B; Krejci, M; Brychtova, Y; Panovska, A; Skuhrova, HF; Burckova, K; Borsky, M; Loja, T; Mayer, J; Pospisilova, S; Doubek, M, 2014: Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY 36(2), p. 165 - 171, doi: 10.1111/ijlh.12149
• Kminkova, J; Mraz, M; Zaprazna, K; Navrkalova, V; Tichy, B; Plevova, K; Malcikova, J; Cerna, K; Rausch, T; Benes, V; Brychtova, Y; Doubek, M; Mayer, J; Pospisilova, S, 2014: Identification of novel sequence variations in microRNAs in chronic lymphocytic leukemia. CARCINOGENESIS 35(5), p. 992 - 1002, doi: 10.1093/carcin/bgt396

2013

• Navrkalova, V; Sebejova, L; Zemanova, J; Kminkova, J; Kubesova, B; Malcikova, J; Mraz, M; Smardova, J; Pavlova, S; Doubek, M; Brychtova, Y; Potesil, D; Nemethova, V; Mayer, J; Pospisilova, S; Trbusek, M, 2013: ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin. HAEMATOLOGICA 98(7), p. 1124 - 1131, doi: 10.3324/haematol.2012.081620
• Kaucka, M; Plevova, K; Pavlova, S; Janovska, P; Mishra, A; Verner, J; Prochazkova, J; Krejci, P; Kotaskova, J; Ovesna, P; Tichy, B; Brychtova, Y; Doubek, M; Kozubik, A; Mayer, J; Pospisilova, S; Bryja, V, 2013: The Planar Cell Polarity Pathway Drives Pathogenesis of Chronic Lymphocytic Leukemia by the Regulation of B-Lymphocyte Migration. CANCER RESEARCH 73(5), p. 1491 - 1501, doi: 10.1158/0008-5472CAN-12-1752
• Mraz, M; Kozubik, KS; Plevova, K; Musilova, K; Tichy, B; Borsky, M; Kuglik, P; Doubek, M; Brychtova, Y; Mayer, J; Pospisilova, S, 2013: The origin of deletion 22q11 in chronic lymphocytic leukemia is related to the rearrangement of immunoglobulin lambda light chain locus. LEUKEMIA RESEARCH 37(7), p. 802 - 808, doi: 10.1016/j.leukres.2013.03.018
• Krejci, M; Doubek, M; Brychtova, Y; Stehlikova, O; Chovancova, J; Tichy, B; Francova, HS; Navratil, M; Tomiska, M; Horky, O; Pospisilova, S; Mayer, J, 2013: Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia. ANNALS OF HEMATOLOGY 92(2), p. 249 - 254, doi: 10.1007/s00277-012-1579-y
• te Raa, GD; Malcikova, J; Pospisilova, S; Trbusek, M; Mraz, M; Le Garff-Tavernier, M; Merle-Beral, H; Lin, K; Pettitt, AR; Merkel, O; Stankovic, T; van Oers, MH; Eldering, E; Stilgenbauer, S; Zenz, T; Kater, AP, 2013: Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia. LEUKEMIA & LYMPHOMA 54(8), p. 1849 - 1853, doi: 10.3109/10428194.2013.796058
• ROBESOVA, B.;M. BAJEROVA;A. VASIKOVA;L. OSTRIZKOVA;J. HAUSNEROVA;J. KYCLOVA;S. POSPISILOVA;J. MAYER;D. DVORAKOVA., 2013: Molekularne biologicka diagnostika mutaci genu KRAS a BRAF u pacientu s kolorektalnim karcinomem - zkusenosti laboratorniho pracoviste. KLINICKA ONKOLOGIE 26, p. 25 - 30
• Khare, V; Lyakhovich, A; Dammann, K; Lang, M; Borgmann, M; Tichy, B; Pospisilova, S; Luciani, G; Campregher, C; Evstatiev, R; Pflueger, M; Hundsberger, H; Gasche, C, 2013: Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1. BIOCHEMICAL PHARMACOLOGY 85(2), p. 234 - 244, doi: 10.1016/j.bcp.2012.10.026
• Malcikova, J; Razga, F; Jurcek, T; Dvorakova, D; Zackova, D; Toskova, M; Sebejova, L; Smardova, J; Oltova, A; Vankova, G; Jurackova, L; Trbusek, M; Pospisilova, S; Mayer, J; Racil, Z, 2013: The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. LEUKEMIA & LYMPHOMA 54(9), p. 2083 - 2087, doi: 10.3109/10428194.2012.762649
• Strefford, JC; Sutton, LA; Baliakas, P; Agathangelidis, A; Malcikova, J; Plevova, K; Scarfo, L; Davis, Z; Stalika, E; Cortese, D; Cahill, N; Pedersen, LB; di Celle, PF; Tzenou, T; Geisler, C; Panagiotidis, P; Langerak, AW; Chiorazzi, N; Pospisilova, S; Os, 2013: Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. LEUKEMIA 27(11), p. 2196 - 2199, doi: 10.1038/leu.2013.98
• Krejci, M; Doubek, M; Dusek, J; Brychtova, Y; Racil, Z; Navratil, M; Tomiska, M; Horky, O; Pospisilova, S; Mayer, J, 2013: Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia. ANNALS OF HEMATOLOGY 92(10), p. 1397 - 1403, doi: 10.1007/s00277-013-1790-5
• Panovska, A; Smolej, L; Lysak, D; Brychtova, Y; Simkovic, M; Motyckova, M; Vodarek, P; Lindtnerova, M; Trbusek, M; Malcikova, J; Pospisilova, S; Mayer, J; Doubek, M, 2013: The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab. EUROPEAN JOURNAL OF HAEMATOLOGY 90(6), p. 479 - 485, doi: 10.1111/ejh.12106

2012

• Doubek, M; Trbusek, M; Malcikova, J; Brychtova, Y; Smardova, J; Lochmanova, J; Panovska, A; Francova, HS; Mraz, M; Tichy, B; Sebejova, L; Navrkalova, V; Plevova, K; Kuglik, P; Mayer, J; Pospisilova, S, 2012: Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia. LEUKEMIA & LYMPHOMA 53(9), p. 1817 - 1819, doi: 10.3109/10428194.2012.658794
• Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP, Cymbalista F, Eichhorst B, Hallek M, Döhner H, Hillmen P, van Oers M, Gribben J, Ghia P, Montserrat E, Stilgenbauer S, Zenz T, 2012: European Research Initiative on CLL (ERIC). ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. LEUKEMIA 26(7), p. 1458 - 61
• ADAM, Z.;M. STORK;L. POUR;M. KREJCI;L. ZAHRADOVA;V. SANDECKA;R. HAJEK;Z. CERMAKOVA;Y. POSPISILOVA;M. NAVRATIL;Z. KRAL;J. MAYER., 2012: Vysledky lecby AL-amyloidozy lecebnymi rezimy obsahujicimi bortezomib, dexametazon a dale cyklofosfamid anebo doxorubucin. VNITRNI LEKARSTVI 58, p. 896 - 903
• Kostareli, E; Gounari, M; Janus, A; Murray, F; Brochet, X; Giudicelli, V; Pospisilova, S; Oscier, D; Foroni, L; di Celle, PF; Tichy, B; Pedersen, LB; Jurlander, J; Ponzoni, M; Kouvatsi, A; Anagnostopoulos, A; Thompson, K; Darzentas, N; Lefranc, MP; Beless, 2012: Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity. LEUKEMIA 26(5), p. 1127 - 1131, doi: 10.1038/leu.2011.311
• Janikova, A; Mareckova, A; Dvorakova, D; Bortlicek, Z; Tichy, B; Navratil, M; Kral, Z; Pospisilova, S; Mayer, J, 2012: A real-time (PCR) for a real life ...? Quantitative evaluation of BCL2/IGH in follicular lymphoma and its implications for clinical practice. EXPERIMENTAL HEMATOLOGY 40(7), p. 528 - 539, doi: 10.1016/j.exphem.2012.02.005
• Pospisilova, S; Gonzalez, D; Malcikova, J; Trbusek, M; Rossi, D; Kater, AP; Cymbalista, F; Eichhorst, B; Hallek, M; Dohner, H; Hillmen, P; van Oers, M; Gribben, J; Ghia, P; Montserrat, E; Stilgenbauer, S; Zenz, T, 2012: ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. LEUKEMIA 26(7), p. 1458 - 1461, doi: 10.1038/leu.2012.25
• MRAZ, M.;M. TRBUSEK;D. DOLEZALOVA;J. MALCIKOVA;J. SUPIKOVA;K. STANO KOZUBIK;B. KANTOROVA;J. MAYER;S. POSPISILOVA., 2012: Identifikace patogeneticky vyznamnych mutaci u chronicke lymfocytarni leukemie pomoci ´sekvenovani nove generace´. TRANSFUZE A HEMATOLOGIE DNES 18, p. 72 - 75
• Dolezalova, D; Mraz, M; Barta, T; Plevova, K; Vinarsky, V; Holubcova, Z; Jaros, J; Dvorak, P; Pospisilova, S; Hampl, A, 2012: MicroRNAs Regulate p21(Waf1/Cip1) Protein Expression and the DNA Damage Response in Human Embryonic Stem Cells. STEM CELLS 30(7), p. 1362 - 1372, doi: 10.1002/stem.1108
• Mraz, M; Pospisilova, S, 2012: MicroRNAs in chronic lymphocytic leukemia: from causality to associations and back. EXPERT REVIEW OF HEMATOLOGY 5(6), p. 579 - 581, doi: 10.1586/EHM.12.54
• Mraz, M; Dolezalova, D; Plevova, K; Kozubik, KS; Mayerova, V; Cerna, K; Musilova, K; Tichy, B; Pavlova, S; Borsky, M; Verner, J; Doubek, M; Brychtova, Y; Trbusek, M; Hampl, A; Mayer, J; Pospisilova, S, 2012: MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. BLOOD 119(9), p. 2110 - 2113, doi: 10.1182/blood-2011-11-394874
• Lochmanova, G; Jedlickova, L; Potesil, D; Tomancova, A; Verner, J; Pospisilova, S; Doubek, M; Mayer, J; Zdrahal, Z, 2012: Potential biomarkers for early detection of acute graft-versus-host disease. PROTEOMICS CLINICAL APPLICATIONS 6(42223), p. 351 - 363, doi: 10.1002/prca.201100104
• te Raa, D; Malcikova, J; Mraz, M; Pospisilova, S; Le Garff-Tavernier, M; Merle-Beral, H; Stankovic, T; van Oers, MHJ; Eldering, E; Stilgenbauer, S; Zenz, T; Kater, AP, 2012: Assessment of p53 Functionality in Chronic Lymphocytic Leukemia by Different Assays; An Eric-Wide Approach.. BLOOD 120(21)
• Lengerova, M; Kocmanova, I; Racil, Z; Hrncirova, K; Pospisilova, S; Mayer, J; Najvar, LK; Wiederhold, NP; Kirkpatrick, WR; Patterson, TF, 2012: Detection and Measurement of Fungal Burden in a Guinea Pig Model of Invasive Pulmonary Aspergillosis by Novel Quantitative Nested Real-Time PCR Compared with Galactomannan and (1,3)-beta-D-Glucan Detection. JOURNAL OF CLINICAL MICROBIOLOGY 50(3), p. 602 - 608, doi: 10.1128/JCM.05356-11
• Agathangelidis, A; Darzentas, N; Hadzidimitriou, A; Brochet, X; Murray, F; Yan, XJ; Davis, Z; van Gastel-Mol, EJ; Tresoldi, C; Chu, CC; Cahill, N; Giudicelli, V; Tichy, B; Pedersen, LB; Foroni, L; Bonello, L; Janus, A; Smedby, K; Anagnostopoulos, A; Merle, 2012: Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. BLOOD 119(19), p. 4467 - 4475, doi: 10.1182/blood-2011-11-393694
• Kozubik, KS; Malcikova, J; Trbusek, M; Tom, N; Doubek, M; Brychtova, Y; Smardova, J; Mayer, J; Pospisilova, S; Tichy, B, 2012: Clonal Selection of TP53 Mutations in Chronic Lymphocytic Leukaemia Detected by Ultra-deep Pyrosequencing. EUROPEAN JOURNAL OF CANCER 48, p. S146 - S146
• Zemanova, J; Sebejova, L; Hylse, O; Paruch, K; Pavlova, S; Mayer, J; Pospisilova, S; Trbusek, M, 2012: Inhibition of Chk1 Kinase Sensitizes Leukemia and Lymphoma Cell Lines with TP53 Mutations to Chemotherapy. BLOOD 120(21)
• Panovska, A; Lysak, D; Smolej, L; Brychtova, Y; Simkovic, M; Motyckova, M; Lindtnerova, M; Trbusek, M; Malcikova, J; Pospisilova, S; Mayer, J; Doubek, M, 2012: The Fate of Chronic Lymphocytic Leukemia Patients After Failure of Fludarabine, Cyclophosphamide, and Rituximab Regimen. BLOOD 120(21)
• Verner, J; Kabathova, J; Tomancova, A; Pavlova, S; Tichy, B; Mraz, M; Brychtova, Y; Krejci, M; Zdrahal, Z; Trbusek, M; Volejnikova, J; Sedlacek, P; Doubek, M; Mayer, J; Pospisilova, S, 2012: Gene expression profiling of acute graft-vs-host disease after hematopoietic stem cell transplantation. EXPERIMENTAL HEMATOLOGY 40(11), p. 899 - 905, doi: 10.1016/j.exphem.2012.06.011

2011

• Janikova, A; Tichy, B; Supikova, J; Stano-Kozubik, K; Pospisilova, S; Kren, L; Vasova, I; Salek, D; Mayer, J, 2011: Gene expression profiling in follicular lymphoma and its implication for clinical practice. LEUKEMIA & LYMPHOMA 52(1), p. 59 - 68, doi: 10.3109/10428194.2010.531412
• Mraz, M; Zent, CS; Church, AK; Jelinek, DF; Wu, XS; Pospisilova, S; Ansell, SM; Novak, AJ; Kay, NE; Witzig, TE; Nowakowski, GS, 2011: Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance. BRITISH JOURNAL OF HAEMATOLOGY 155(1), p. 53 - 64, doi: 10.1111/j.1365-2141.2011.08794.x
• Trbusek, M; Smardova, J; Malcikova, J; Sebejova, L; Dobes, P; Svitakova, M; Vranova, V; Mraz, M; Francova, HS; Doubek, M; Brychtova, Y; Kuglik, P; Pospisilova, S; Mayer, J, 2011: Missense Mutations Located in Structural p53 DNA-Binding Motifs Are Associated With Extremely Poor Survival in Chronic Lymphocytic Leukemia. JOURNAL OF CLINICAL ONCOLOGY 29(19), p. 2703 - 2708, doi: 10.1200/JCO.2011.34.7872
• Kaucka, M; Krejci, P; Plevova, K; Pavlova, S; Prochazkova, J; Janovska, P; Valnohova, J; Kozubik, A; Pospisilova, S; Bryja, V, 2011: Post-translational modifications regulate signalling by Ror1. ACTA PHYSIOLOGICA 203(3), p. 351 - 362, doi: 10.1111/j.1748-1716.2011.02306.x
• Doubek, M; Mayer, J; Obrtlikova, P; Smolej, L; Cmunt, E; Schwarz, J; Brejcha, M; Kozmon, P; Pospisilova, S; Brychtova, Y; Pospisil, Z; Trneny, M, 2011: Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice. EUROPEAN JOURNAL OF HAEMATOLOGY 87(2), p. 130 - 137, doi: 10.1111/j.1600-0609.2011.01639.x
• Krejci, M; Brychtova, Y; Doubek, M; Tomiska, M; Navratil, M; Racil, Z; Dvorakova, D; Horky, O; Lengerova, M; Pospisilova, S; Mayer, J, 2011: Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. NEOPLASMA 58(5), p. 406 - 414, doi: 10.4149/neo_2011_05_406
• Khare, V; Lyakhovich, A; Lang, M; Tichy, B; Pospisilova, S; Luciani-Torres, MG; Gasche, C, 2011: Inhibition of PAK-1 by Mesalazine Increases Cell Adhesion in Colorectal Cancer Cells. GASTROENTEROLOGY 140(5), p. S402 - S402
• Mraz, M; Plevova, K; Dolezalova, D; Stano-Kozubik, K; Mayerova, V; Cerna, K; Musilova, K; Pavlova, S; Tichy, B; Lochmanova, J; Doubek, M; Brychtova, Y; Trbusek, M; Hampl, A; Mayer, J; Pospisilova, S, 2011: The Regulation, Targets and Clinical Relevance of Microrna Mir-650 in Chronic Lymphocytic Leukemia (CLL). BLOOD 118(21), p. 1655 - 1656
• Lochmanova, J; Mraz, M; Navrkalova, V; Dvorakova, B; Tichy, B; Plevova, K; Sebejova, L; Malcikova, J; Pavlova, S; Benes, V; Rausch, T; Brychtova, Y; Doubek, M; Trbusek, M; Mayer, J; Pospisilova, S, 2011: Mutational Analysis of Mir-29 Family Members in Chronic Lymphocytic Leukemia. BLOOD 118(21), p. 772 - 772
• Vargova, K; Curik, N; Burda, P; Basova, P; Kulvait, V; Pospisil, V; Savvulidi, F; Kokavec, J; Necas, E; Berkova, A; Obrtlikova, P; Karban, J; Mraz, M; Pospisilova, S; Mayer, J; Trneny, M; Zavadil, J; Stopka, T, 2011: MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. BLOOD 117(14), p. 3816 - 3825, doi: 10.1182/blood-2010-05-285064

2010

• Zenz, T; Vollmer, D; Trbusek, M; Smardova, J; Benner, A; Soussi, T; Helfrich, H; Heuberger, M; Hoth, P; Fuge, M; Denzel, T; Habe, S; Malcikova, J; Kuglik, P; Truong, S; Patten, N; Wu, L; Oscier, D; Ibbotson, R; Gardiner, A; Tracy, I; Lin, K; Pettitt, A; Pospisilova, S; Mayer, J; Hallek, M; Dohner, H; Stilgenbauer, S, 2010: TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. LEUKEMIA 24(12), p. 2072 - 2079, doi: 10.1038/leu.2010.208
• Malcikova, J; Tichy, B; Damborsky, J; Kabathova, J; Trbusek, M; Mayer, J; Pospisilova, S, 2010: Analysis of the DNA-binding activity of p53 mutants using functional protein microarrays and its relationship to transcriptional activation. BIOLOGICAL CHEMISTRY 391(2 III), p. 197 - 205, doi: 10.1515/BC.2010.027
• Barta, Tomas; Vinarsky, Vladimir; Holubcova, Zuzana; Dolezalova, Dasa; Verner, Jan; Pospisilova, Sarka; Dvorak, Petr; Hampl, Ales, 2010: Human Embryonic Stem Cells Are Capable of Executing G1/S Checkpoint Activation. STEM CELLS 28(7), p. 1143 - 1152, doi: 10.1002/stem.451
• Kotaskova, Jana; Tichy, Boris; Trbusek, Martin; Francova, Hana Skuhrova; Kabathova, Jitka; Malcikova, Jitka; Doubek, Michael; Brychtova, Yvona; Mayer, Jiri; Pospisilova, Sarka, 2010: High Expression of Lymphocyte-Activation Gene 3 (LAG3) in Chronic Lymphocytic Leukemia Cells Is Associated with Unmutated lmmunoglobulin Variable Heavy Chain Region (IGHV) Gene and Reduced Treatment-Free Survival. JOURNAL OF MOLECULAR DIAGNOSTICS 12(3), p. 328 - 334, doi: 10.2353/jmoldx.2010.090100
• Hrncirova, Kristyna; Lengerova, Martina; Kocmanova, Iva; Racil, Zdenek; Volfova, Pavlina; Palousova, Dita; Moulis, Mojmir; Weinbergerova, Barbora; Winterova, Jana; Toskova, Martina; Pospisilova, Sarka; Mayer, Jiri, 2010: Rapid Detection and Identification of Mucormycetes from Culture and Tissue Samples by Use of High-Resolution Melt Analysis. JOURNAL OF CLINICAL MICROBIOLOGY 48(9), p. 3392 - 3394, doi: 10.1128/JCM.01109-10
• Mraz, Marek; Zent, Clive S.; Church, Amy K.; Baig, Nisar A.; Jelinek, Diane F.; Wu, Xiaosheng; Pospisilova, Sarka; Ansell, Stephen M.; Novak, Anne J.; Witzig, Thomas E.; Nowakowski, Grzegorz S., 2010: Interactions with the Microenvironment Protect Lymphoma B-Cells From Rituximab Induced Apoptosis and Could Represent a Therapeutic Target.. BLOOD 116(21), p. 1284 - 1284

2009

• MALCIKOVA, J., SMARDOVA, J., ROCNOVA, L., TICHY, B., KUGLIK, P., VRANOVA, V., CEJKOVA, S., SVITAKOVA, M., SKUHROVA FRANCOVA, H., BRYCHTOVA, Y., DOUBEK, M., BREJCHA, M., KLABUSAY, M., MAYER, J., POSPISILOVA, S., TRBUSEK, M., 2009: Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival and response to DNA damage. BLOOD 114(26), p. 5307 - 5314
• STROS, M., POLANSKA, E., STRUNCOVA, S., POSPISILOVA, S., 2009: HMGB1 and HMGB2 proteins up regulate cellular expression of human topoisomerase II alpha. NUCLEIC ACIDS RESEARCH 37(7), p. 2070 - 2086
• MRAZ, M., MALINOVA, K., KOTASKOVA, J., PAVLOVA, S., TICHY, B., MALCIKOVA, J., STANO-KOZUBIK, K., SMARDOVA, J., BRYCHTOVA, Y., DOUBEK, M., TRBUSEK, M., MAYER, J., POSPISILOVA, S., 2009: miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. LEUKEMIA 23(6), p. 1159 - 1163
• CEJKOVA, S., ROCNOVA, L., POTESIL, D., SMARDOVA, J., NOVAKOVA, V., CHUMCHALOVA, J., ZEZULKOVA, D., BORSKY, M., DOUBEK, M., BRYCHTOVA, Y., POSPISILOVA, S., KLABUSAY, M., MAYER, K., TRBUSEK, M., 2009: Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine. EUROPEAN JOURNAL OF HAEMATOLOGY , p. 133 - 142
• Mraz, Marek; Malinova, Karla; Pavlova, Sarka; Tichy, Boris; Kozubik, Katerina Stano; Malcikova, Jitka; Borsky, Marek; Verner, Jan; Doubek, Michael; Brychtova, Yvona; Trbusek, Martin; Mayer, Jiri; Pospisilova, Sarka, 2009: Detail Characterization of 22q11 Deletion and Mir-650 Role in CLL Patients. BLOOD 114(22), p. 507 - 508

• Single cell analysis: a modern tool to study clonal evolution in high-risk patients with chronic lymphocytic leukemia, , 2020 - 2023
• Healthcare Alliance for Resourceful Medicines Offensive Against Neoplasms in Hematology-Plus, , 2020 - 2023
• Comprehensive prognostic and predictive panel for chronic lymphocytic leukemia: a next-generation sequencing tool suitable for clinical practice and study of genetic architecture behind the disease progress, Ministry of Health of the CR, 2019 - 2022
• Establishment in Multidisciplinary Healthcare Education SYStem (Nemhesys), , 2020 - 2022
• Involvement of Czech Translational Medicine Infrastructure to the European Advanced Translational Research Infrastructure in Medicine, , 2020 - 2022
• Analýza Českých Genomů pro Teranostiku, Ministerstvo školství, mládeže a tělovýchovy ČR, 2019 - 2022
• Fostering Palliative Care of Adults and Children with Cancer through Advanced Patient Reported Outcome Systems, Evropská unie, 2019 - 2022
• Alternative mechanisms of deregulation of the p53 pathway in chronic lymphocytic leukemia, Grantová agentura ČR, 2019 - 2021
• Modernizace a rozšíření přístrojového vybavení Národního centra lékařské genomiky, , 2020 - 2021
• Personalizovaná medicína - diagnostika a terapie, , 2019 - 2020
• Individuální rozdíly v diferenciaci mezi reprezentací sebe a druhých lidí (GA15-16738S), Grantová agentura ČR, 2015 - 2017
• Understanding empathy using a second person neuroscience approach – a multimodal hyperscanning study combining fMRI and scalp EEG (7AMB15AT015), Ministerstvo školství, mládeže a tělovýchovy ČR, 2015 - 2016
• Expression and function of activation-induced cytidine deaminase splice variants in normal B cell physiology and chronic lymphocytic leukemia (3SGA5792), Jihomoravský kraj, 2013 - 2016
• Functional and structural changes of microRNAs in lymphoproliferative malignancies and their impact on prognosis and prediction of therapy response (NT11218), Ministry of Health - Ministry of Health´s Departmental Research and Development Programme III (2010-2015), 2010 - 2015
• CEITEC - Central European Institute of Technology (CZ.1.05/1.1.00/02.0068), Ministerstvo školství, mládeže a tělovýchovy ČR, 2011 - 2015
• NGS-PTL - Next Generation Sequencing platform for targeted Personalized Therapy of Leukemia (306242), Evropská unie, 2012 - 2015
• SuPReMMe - Podpora profesního růstu a mezinárodní integrace výzkumných týmů v oblasti molekulární medicíny (CZ.1.07/2.3.00/20.0045), Ministerstvo školství, mládeže a tělovýchovy ČR, 2011 - 2014
• Optimalizace metodiky analýzy a hodnocení simultánního EEG-fMRI u pacientů s farmakorezistentní epilepsií (GAP304/11/1318), Grantová agentura ČR, 2011 - 2013
• Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies (MSM0021622430), Ministerstvo školství, mládeže a tělovýchovy ČR, 2007 - 2013
• Real-time PCR soupravy pro diagnostiku v onkologii (FR-TI2/254), Ministerstvo průmyslu a obchodu ČR, 2010 - 2013
• Involvement of nuclear HMGB proteins in sensitizing of human cells to anticancer drugs inhibiting DNA topoizomerases (GAP301/10/0590), Czech Science Foundation - Standard Grants, 2010 - 2012
• Analysis of changes in genome and its expression in chronic lymphocytic leukemia patients during the disease development (NS10439), Ministry of Health - Departmental Programme of Research and Development (2008-2011), 2009 - 2011